Eli Lilly & Co. (LLY)
1251.61
+42.87
(+3.55%)
USD |
NYSE |
Oct 15, 16:00
1258.00
+6.39
(+0.51%)
Pre-Market: 07:32
Eli Lilly SG&A Expense (TTM) : 12.24B for June 30, 2026
SG&A Expense (TTM) Chart
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 12.24B |
| March 31, 2026 | 11.56B |
| December 31, 2025 | 11.09B |
| September 30, 2025 | 10.39B |
| June 30, 2025 | 9.746B |
| March 31, 2025 | 9.110B |
| December 31, 2024 | 8.594B |
| September 30, 2024 | 8.094B |
| June 30, 2024 | 7.798B |
| March 31, 2024 | 7.606B |
| December 31, 2023 | 7.403B |
| September 30, 2023 | 7.122B |
| June 30, 2023 | 6.932B |
| March 31, 2023 | 6.632B |
| December 31, 2022 | 6.440B |
| September 30, 2022 | 6.389B |
| June 30, 2022 | 6.353B |
| March 31, 2022 | 6.414B |
| December 31, 2021 | 6.432B |
| September 30, 2021 | 6.394B |
| June 30, 2021 | 6.385B |
| March 31, 2021 | 6.148B |
| December 31, 2020 | 6.121B |
| September 30, 2020 | 6.265B |
| June 30, 2020 | 6.109B |
| Date | Value |
|---|---|
| March 31, 2020 | 6.246B |
| December 31, 2019 | 6.214B |
| September 30, 2019 | 6.209B |
| June 30, 2019 | 6.254B |
| March 31, 2019 | 6.154B |
| December 31, 2018 | 5.975B |
| September 30, 2018 | 6.062B |
| June 30, 2018 | 6.160B |
| March 31, 2018 | 6.382B |
| December 31, 2017 | 6.588B |
| September 30, 2017 | 6.598B |
| June 30, 2017 | 6.608B |
| March 31, 2017 | 6.523B |
| December 31, 2016 | 6.452B |
| September 30, 2016 | 6.460B |
| June 30, 2016 | 6.471B |
| March 31, 2016 | 6.483B |
| December 31, 2015 | 6.533B |
| September 30, 2015 | 6.534B |
| June 30, 2015 | 6.631B |
| March 31, 2015 | 6.659B |
| December 31, 2014 | 6.621B |
| September 30, 2014 | 6.774B |
| June 30, 2014 | 6.755B |
| March 31, 2014 | 6.958B |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Johnson & Johnson | 19.22B |
| Merck & Co., Inc. | 11.14B |
| Pfizer Inc. | 13.72B |
| Bristol Myers Squibb Co. | 7.413B |
| Structure Therapeutics, Inc. | 74.01M |